Custom vaccine targets ovarian Cancer's unique mutations
NCT ID NCT03839524
Summary
This early-stage trial tested a personalized cancer vaccine called TG4050 in patients with ovarian, fallopian tube, or peritoneal cancer who were in remission after initial treatment. The main goal was to check if the vaccine was safe and well-tolerated. Researchers also looked for early signs that the vaccine might help prevent the cancer from coming back by training the immune system to recognize each patient's unique cancer mutations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
IUCT Toulouse
Toulouse, 31100, France
-
Institut Curie
Paris, 75005, France
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Phoenix
Phoenix, Arizona, 85259, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.